An apparatus for autologous blood transfusion for cancer patients

Abstract

The utility model provides a kind of autologous blood transfusion device for tumor patient, with such features, comprising: collecting device, including suction nozzle and with the blood storage tank of suction nozzle connection by pipeline;Cleaning device, with the blood storage tank is connected by pipeline, for washing the blood collected and separates red blood cell;Sampling device, with the cleaning device is connected by pipeline, for collecting blood sample;Intermediate bag, with the sampling device is connected by pipeline;At least one filter recovery device, including filter and blood bag;Blood transfusion device, with the blood bag is connected by pipeline;Wherein, filter and intermediate bag are connected by pipeline, the position of filter is lower than intermediate bag, blood bag and filter are connected by pipeline, the position of blood bag is lower than filter.

Description

Technical Field

[0001] This utility model relates to the technical field of medical devices, specifically to an autologous blood transfusion device for cancer patients. Background Technology

[0002] Autologous transfusion sets are medical devices used to collect, store, and reinfuse a patient's own blood, and are widely used in surgery and other treatments. Their main function is to collect blood from a patient before or during surgery, process it, and then reinfuse it into the patient, thereby reducing the need for allogeneic blood transfusions and lowering transfusion-related risks and costs.

[0003] Currently, because cancer patients may have tumor cells in their blood, these cells could cause the tumor to spread or metastasize after reinfusion, worsening their condition. Autologous blood transfusion is limited, so allogeneic blood transfusion is often used, increasing the burden on blood supply and treatment costs. Utility Model Content

[0004] This invention was developed to solve the above-mentioned problems, and its purpose is to provide an autologous blood transfusion device for cancer patients.

[0005] This invention provides an autologous blood transfusion device for cancer patients, characterized by comprising: a collection device including a suction nozzle and a blood storage tank connected to the suction nozzle via a tubing; a cleaning device connected to the blood storage tank via a tubing for cleaning the collected blood and separating red blood cells; a sampling device connected to the cleaning device via a tubing for collecting blood samples; an intermediate bag connected to the sampling device via a tubing; at least one filtration and recovery device including a filter and a blood bag; and a transfusion set connected to the blood bag via a tubing; wherein the filter is connected to the intermediate bag via a tubing, with the filter positioned below the intermediate bag, and the blood bag is connected to the filter via a tubing, with the blood bag positioned below the filter.

[0006] The autologous blood transfusion device for cancer patients provided by this utility model may also include an anticoagulant bag connected to the pipeline between the suction nozzle and the blood storage tank.

[0007] The autologous blood transfusion device for cancer patients provided by this utility model may also have the following feature: an external negative pressure source is connected to the blood storage tank.

[0008] The autologous blood reinfusion device for cancer patients provided by this utility model may also have the following features: the cleaning device includes: a centrifuge cup connected to a blood storage tank via a pipeline, a blood pump disposed on the pipeline between the centrifuge cup and the blood storage tank, a washing bag connected to the centrifuge cup via a pipeline, a cleaning pump disposed on the pipeline between the washing bag and the centrifuge cup, and a waste bag connected to the centrifuge cup.

[0009] The autologous blood reinfusion device for cancer patients provided by this utility model may also have the following features: the sampling device includes: a three-way valve connected to a centrifuge cup via a pipeline, and a specimen bag connected to the three-way valve via a pipeline.

[0010] The autologous blood transfusion device for cancer patients provided by this utility model may also include the following feature: an output pump is provided on the pipeline between the centrifuge cup and the three-way valve.

[0011] The autologous blood transfusion device for cancer patients provided by this utility model may also have the following feature: the intermediate bag and the three-way valve are connected by a pipeline.

[0012] The autologous blood transfusion device for cancer patients provided by this utility model may also have the following features: the number of filtration and recovery devices is two or more, the filter in each filtration and recovery device is connected to the intermediate bag through a pipeline, and the blood bag in each filtration and recovery device is connected to the transfusion set through a pipeline.

[0013] The autologous blood transfusion device for cancer patients provided by this utility model may also have the following feature: the pore size of the filter membrane in the filter is 5-10μm.

[0014] Functions and effects of utility models

[0015] According to the autologous blood transfusion device for cancer patients involved in this utility model, by setting up a sampling device, there is no need to take additional samples from the processed and recovered blood for testing, reducing the risk of blood contamination. By incorporating a filter, white blood cells and tumor cells in the blood can be filtered out. Furthermore, the filter is positioned lower than the intermediate bag, and there is no additional power device such as a pump between the intermediate bag and the filter. The blood in the intermediate bag flows naturally to the filter by gravity, preventing tumor cells from being squeezed and deformed by the pressure of the power device and entering the blood bag along with the filter. This allows cancer patients to use the autologous blood transfusion device for cancer patients, reducing the burden on blood supply and the treatment costs for cancer patients. Attached Figure Description

[0016] Figure 1 This is a schematic diagram of the structure of the autologous blood transfusion device for tumor patients in an embodiment of this utility model.

[0017] Explanation of symbols for main components:

[0018] In the diagram: 100. Autologous blood transfusion device for cancer patients; 1. Suction nozzle; 2. Anticoagulant bag; 3. Blood storage tank; 4. Blood pump; 5. Centrifuge cup; 6. Washing fluid bag; 7. Waste fluid bag; 8. Intermediate bag; 9. Filter; 10. Blood bag; 11. Specimen bag; 12. Three-way valve; 13. Cleaning pump; 14. Output pump; 15. Transfusion set. Detailed Implementation

[0019] The technical solutions in the embodiments of this application will be clearly and completely described below with reference to the accompanying drawings. Obviously, the described embodiments are only some embodiments of this application, and not all embodiments. All other embodiments obtained by those skilled in the art based on the embodiments of this application without creative effort are within the scope of protection of this application.

[0020] In the description of this application, it should be noted that the terms "upper," "lower," "inner," "outer," "top / bottom," etc., indicating the orientation or positional relationship are based on the orientation or positional relationship shown in the accompanying drawings, and are only for the convenience of describing this application and simplifying the description, and do not indicate or imply that the device or element referred to must have a specific orientation, or be constructed and operated in a specific orientation, and therefore should not be construed as a limitation of this application. Furthermore, the terms "first" and "second" are used for descriptive purposes only and should not be construed as indicating or implying relative importance.

[0021] In the description of this application, it should be noted that, unless otherwise expressly specified and limited, the terms "installation," "connection," and "linking" should be interpreted broadly. For example, they can refer to a fixed connection, a detachable connection, or an integral connection; they can refer to a mechanical connection, an electrical connection, or a connection that allows communication between them; they can refer to a direct connection or an indirect connection through an intermediate medium; they can refer to the internal communication between two components or the interaction between two components. Those skilled in the art can understand the specific meaning of the above terms in this application according to the specific circumstances.

[0022] To make the technical means, creative features, objectives and effects of this utility model easy to understand, the following embodiments, in conjunction with the accompanying drawings, will specifically illustrate the autologous blood transfusion device for tumor patients of this utility model.

[0023] Figure 1 This is a schematic diagram of the structure of the autologous blood transfusion device 100 for tumor patients in this embodiment of the present invention.

[0024] like Figure 1 As shown, the autologous blood transfusion device 100 for tumor patients in this embodiment includes: a collection device, an anticoagulant bag 2, a cleaning device, a sampling device, an intermediate bag 8, at least one filtration and recovery device, and a transfusion set 15.

[0025] The collection device includes a suction nozzle 1 and a blood storage tank 3 connected to the suction nozzle 1 via tubing. The suction nozzle 1 is used to connect to a patient's blood vessel for drawing blood.

[0026] An anticoagulant bag 2 is connected to the tubing between the suction nozzle 1 and the blood storage tank 3, and contains an anticoagulant to prevent blood clotting. As blood is drawn through the suction nozzle 1, the anticoagulant bag 2 is opened, and the anticoagulant flows into the blood storage tank 3 along with the drawn blood, preventing the collected blood from clotting. An external negative pressure source is connected to the blood storage tank 3 to provide a certain negative pressure to ensure the smooth progress of the extraction process.

[0027] The cleaning device is connected to the blood storage tank 3 via pipeline and is used to clean the collected blood and separate red blood cells. The cleaning device includes a blood pump 4, a centrifuge cup 5, a washing fluid bag 6, a cleaning pump 13, and a waste fluid bag 7.

[0028] The blood pump 4 is installed on the pipeline between the centrifuge cup 5 and the blood storage tank 3, and is used to pump the blood collected in the blood storage tank 3 into the centrifuge cup 5.

[0029] Centrifuge cup 5 is connected to blood storage tank 3 via a pipeline and is used to centrifuge blood containing washing solution to separate the cells in the blood from the liquid.

[0030] The washing bag 6 is connected to the centrifuge cup 5 via tubing and contains a solution for washing the blood, usually physiological saline.

[0031] The cleaning pump 13 is installed on the pipeline between the washing liquid bag 6 and the centrifuge cup 5, and is used to pump the cleaning liquid in the washing liquid bag 6 into the centrifuge cup 5.

[0032] Waste liquid bag 7 is connected to centrifuge cup 5. After the collected blood is washed and centrifuged in centrifuge cup 5, the waste liquid (supernatant produced by centrifugation) containing cytoplasm, activated coagulation factors, free hemoglobin and anticoagulant flows into waste liquid bag 7, leaving the lower layer of blood containing red blood cells.

[0033] Specifically, during the blood washing and centrifugation process, the washing solution in the washing bag 6 is continuously pumped into the centrifuge cup 5, which continues to rotate. Simultaneously, waste liquid flows into the waste liquid bag 7, until the washing and centrifugation process of all collected blood is completed. After the washing and centrifugation process is finished, the volume of blood in the centrifuge cup 5 is equivalent to the volume of the centrifuge cup 5. When calculating the total volume of collected blood, the total volume of centrifuged blood can be obtained using the volume of the centrifuge cup 5 and the number of collection cycles.

[0034] The sampling device and the cleaning device are connected by tubing and are used to collect blood samples. The sampling device includes a three-way valve 12, a specimen bag 11, and an output pump 14.

[0035] The three-way valve 12 is connected to the centrifuge cup 5 via a pipeline and is used to control the direction of blood flow.

[0036] The output pump 14 is installed on the pipeline between the centrifuge cup 5 and the three-way valve 12, and is used to pump the blood containing red blood cells in the centrifuge cup 5 to the three-way valve 12.

[0037] The specimen bag 11 is connected to the three-way valve 12 via a pipeline for collecting blood samples.

[0038] The intermediate bag 8 and the three-way valve 12 are connected by a pipeline.

[0039] Specifically, when a blood sample needs to be collected, the opening direction of the three-way valve 12 is adjusted, allowing blood to flow into the specimen bag 11. The blood in the specimen bag 11 is used to measure hematocrit. When the blood sample collection is complete, the opening direction of the three-way valve 12 is adjusted, allowing blood to flow into the intermediate bag 8.

[0040] Hematocrit measurements can determine the number of red blood cells in the blood. Combined with the total volume of blood collected, this allows for a more accurate prediction of the amount of blood loss during surgery, enabling timely adjustments to transfusion strategies.

[0041] In the autologous blood transfusion device 100 for cancer patients in this embodiment, there are two or more filtration and recovery devices. These filtration and recovery devices can perform filtration and recovery simultaneously, which helps to improve filtration and recovery efficiency.

[0042] Each filtration and recovery unit includes a filter 9 and a blood bag 10. The filter 9 in each filtration and recovery unit is connected to the intermediate bag 8 via a conduit, and the filter 9 is positioned below the intermediate bag 8. The blood bag 10 in each filtration and recovery unit is connected to its corresponding filter 9 via a conduit, and the blood bag 10 is positioned below its corresponding filter 9.

[0043] The pore size of the filter membrane in filter 9 is 5-10 μm.

[0044] There is no additional power device such as a pump between the intermediate bag 8 and the filter 9. The blood in the intermediate bag 8 flows naturally to the filter 9 by gravity, where white blood cells and tumor cells are filtered out, and then the blood flows to the blood bag 10 for recycling.

[0045] Each blood bag 10 of the filtration and recovery device is connected to the blood transfusion set 15 through a pipeline. The blood transfusion set 15 is used to return the blood in the blood bag 10 to the patient.

[0046] Functions and effects of the embodiments

[0047] According to the autologous blood transfusion device 100 for cancer patients involved in this embodiment, by setting up a sampling device, there is no need to take additional samples from the processed and recovered blood for testing, reducing the risk of blood contamination. By setting up a filter 9, white blood cells and tumor cells in the blood can be filtered out. Moreover, the filter 9 is positioned lower than the intermediate bag 8, and there is no additional power device such as a pump between the intermediate bag 8 and the filter 9. The blood in the intermediate bag 8 flows naturally to the filter 9 by gravity, avoiding the situation where tumor cells are squeezed and deformed by the pressure of the power device and enter the blood bag 10 along with the filter 9. This allows cancer patients to use the autologous blood transfusion device 100 for autologous blood transfusion, reducing the burden on blood supply and the treatment costs for cancer patients.

[0048] There are two or more filter recovery devices, which can perform filter recovery simultaneously, thus improving the filter recovery efficiency.

[0049] By incorporating a three-way valve 12, the direction of blood flow can be more easily controlled. Hematocrit measurements can determine the red blood cell count in the blood, and by combining this with the total collected blood volume, the amount of blood loss during surgery can be estimated more accurately, allowing for timely adjustments to the transfusion strategy.

[0050] Those skilled in the art should understand that this utility model is not limited to the above embodiments. The embodiments and descriptions in the specification are merely illustrative of the principles of this utility model. Various changes and modifications can be made to this utility model without departing from its spirit and scope, and all such changes and modifications fall within the scope of the claimed utility model. The scope of protection of this utility model is defined by the appended claims and their equivalents.

Claims

1. A device for autologous blood reinfusion in cancer patients, characterized in that, include: Collection device, including a suction nozzle and a blood storage tank connected to the suction nozzle via tubing; A cleaning device, connected to the blood storage tank via a pipeline, is used to clean the collected blood and separate red blood cells; A sampling device, connected to the cleaning device via a pipeline, is used to collect blood samples; The intermediate bag is connected to the sampling device via a pipeline; At least one filtration and recovery device, including a filter and a blood bag; A blood transfusion set is connected to the blood bag via tubing; The filter is connected to the intermediate bag via a pipeline, and the filter is positioned lower than the intermediate bag. The blood bag is connected to the filter via a pipeline, and the blood bag is positioned lower than the filter.

2. The autologous blood transfusion device for cancer patients according to claim 1, characterized in that, Also includes: An anticoagulant bag is connected to the tubing between the suction nozzle and the blood storage tank.

3. The autologous blood transfusion device for cancer patients according to claim 1, characterized in that: in, The blood storage tank is connected to an external negative pressure source.

4. The autologous blood transfusion device for cancer patients according to claim 1, characterized in that: in, The cleaning device includes: The centrifuge cup is connected to the blood storage tank via a pipeline. A blood pump is installed on the tubing between the centrifuge cup and the blood storage tank. The washing solution bag is connected to the centrifuge cup via tubing. A cleaning pump is installed on the pipeline between the washing solution bag and the centrifuge cup. Waste liquid bag, connected to the centrifuge cup.

5. The autologous blood transfusion device for cancer patients according to claim 4, characterized in that: in, The sampling device includes: A three-way valve is connected to the centrifuge cup via a pipeline. The specimen bag is connected to the three-way valve via a pipeline.

6. The autologous blood transfusion device for cancer patients according to claim 5, characterized in that, Also includes: An output pump is installed on the pipeline between the centrifuge cup and the three-way valve.

7. The autologous blood transfusion device for cancer patients according to claim 5, characterized in that, Also includes: The intermediate bag and the three-way valve are connected by a pipeline.

8. The autologous blood transfusion device for cancer patients according to claim 1, characterized in that: in, The number of the filtration and recovery devices is two or more, and the filter in each filtration and recovery device is connected to the intermediate bag through a pipeline, and the blood bag in each filtration and recovery device is connected to the blood transfusion set through a pipeline.

9. The autologous blood transfusion device for tumor patients according to claim 8, characterized in that: in, The filter membrane in the filter has a pore size of 5-10 μm.

Images